Theratechnologies Net debt/EBITDA
Quel est le Net debt/EBITDA de Theratechnologies?
Le Net debt/EBITDA de Theratechnologies, Inc. est -4.31
Quelle est la définition de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA des entreprises dans Health Care secteur sur TSX par rapport à Theratechnologies
Que fait Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Entreprises avec net debt/ebitda similaire à Theratechnologies
- Castor Maritime a Net debt/EBITDA de -4.32
- BigCommerce a Net debt/EBITDA de -4.32
- EVS Broadcast Equipment S.A a Net debt/EBITDA de -4.32
- Global Indemnity a Net debt/EBITDA de -4.31
- Align Technology a Net debt/EBITDA de -4.31
- TG Therapeutics Inc a Net debt/EBITDA de -4.31
- Theratechnologies a Net debt/EBITDA de -4.31
- Natus Medical Inc a Net debt/EBITDA de -4.31
- Telefonaktiebolaget LM Ericsson (publ) a Net debt/EBITDA de -4.30
- Morris a Net debt/EBITDA de -4.30
- Ortho Regenerative Technologies a Net debt/EBITDA de -4.30
- Marine Products Corp a Net debt/EBITDA de -4.30
- Ramsdens PLC a Net debt/EBITDA de -4.30